Skip to main content
Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
892.70
+1.38 (0.15%)
At close: Oct 25, 2024, 4:00 PM
891.81
-0.89 (-0.10%)
After-hours: Oct 25, 2024, 7:14 PM EDT

Eli Lilly Revenue by Segment
Period Ending Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Diabetes Revenue
20.97B 19.67B 17.90B 16.84B 15.27B 14.46B 14.12B 13.73B
Diabetes Revenue Growth
37.36% 35.97% 26.78% 22.67% 13.38% 9.68% 9.73% 10.95%
Oncology Revenue
7.11B 6.66B 6.43B 5.97B 5.67B 5.67B 5.42B 5.54B
Oncology Revenue Growth
25.46% 17.51% 18.46% 7.85% -0.92% -1.31% -7.25% -4.13%
Immunology Revenue
3.85B 3.80B 3.63B 3.51B 3.37B 3.34B 3.37B 3.51B
Immunology Revenue Growth
14.21% 13.54% 7.70% 0.01% -3.45% -0.48% 8.46% 28.56%
Neuroscience Revenue
2.91B 2.88B 2.90B 1.51B 1.51B 1.55B 1.63B 1.71B
Neuroscience Revenue Growth
92.66% 86.18% 77.83% -11.84% -17.58% -18.56% -14.25% -11.16%
Other Revenue
1.09B 1.12B 1.22B 1.69B 1.87B 3.52B 4.70B 4.59B
Other Revenue Growth
-41.83% -68.12% -74.00% -63.16% -61.08% -14.78% 16.37% 16.91%

Revenue by Geography
Period Ending Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
US Revenue
23.05B 21.79B 19.99B 19.05B 17.45B 18.19B 18.71B 18.27B
US Revenue Growth
32.07% 19.80% 6.88% 4.23% -3.28% 8.20% 15.24% 18.63%
Europe Revenue
6.52B 6.17B 5.91B 4.40B 4.32B 4.30B 4.37B 4.41B
Europe Revenue Growth
50.93% 43.62% 35.21% -0.34% -4.42% -10.00% -9.53% -7.67%
Rest of World Revenue
3.17B 2.95B 3.02B 2.88B 2.77B 2.85B 2.79B 2.85B
Rest of World Revenue Growth
14.14% 3.30% 8.23% 0.86% -2.49% 5.55% 7.88% 14.80%
China Revenue
1.54B 1.54B 1.51B 1.47B 1.42B 1.45B 1.48B 1.54B
China Revenue Growth
8.75% 5.98% 2.35% -4.53% -16.81% -12.56% -7.92% 2.74%
Japan Revenue
1.65B 1.67B 1.63B 1.73B 1.72B 1.75B 1.89B 1.99B
Japan Revenue Growth
-4.35% -4.28% -13.70% -13.48% -21.81% -26.18% -24.40% -22.13%

Operating Expense Breakdown
Period Ending Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Research and Development
9.31B 8.75B 8.14B 7.57B 7.19B 7.15B 7.06B 6.95B
Research and Development Growth
29.52% 22.26% 15.30% 8.84% 2.35% 3.62% 5.99% 8.98%
Marketing, Selling, and Administrative
7.40B 7.12B 6.93B 6.63B 6.44B 6.39B 6.35B 6.41B
Marketing, Selling, and Administrative Growth
14.95% 11.46% 9.12% 3.40% 0.14% -0.07% -0.50% 4.33%
Acquired In-Process Research and Development
3.80B 3.42B 504.60M 847.90M 908.50M 1.11B 1.22B 823.70M
Acquired In-Process Research and Development Growth
318.25% 208.95% -58.68% 2.94% -6.35% 23.08% 69.37% -10.48%
Impairment, Restructuring, and Other
6.77M - - - 244.60M 311.00M - -
Impairment, Restructuring, and Other Growth
-97.23% - - - -22.62% - - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.